Share capital

Total Voting Rights

Retrieved on: 
Thursday, April 1, 2021
Corporate finance, Corporate law, Financial economics, Corporations, Finance, Stock market, Equity securities, Issued shares, Common stock, Share capital

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • In conformity with 5.6.1R of the Disclosure Guidance and Transparency Rules, Arix Bioscience plc announces that its total issued share capital at the close of business on 31 March 2021 comprised 135,609,653 Ordinary Shares of 0.001 pence each fully paid.
  • This figure includes 629,000 Ordinary Shares which are held in Treasury, leaving a balance of 134,980,653 Ordinary Shares with voting rights.

[Correction] GOGL – Special General Meeting

Retrieved on: 
Friday, March 26, 2021
Financial capital, Bond valuation, Par value, Valuation, Share capital, Finance, Corporate finance, Financial economics, Stock market, Financial capital, Bond valuation, Par value, Valuation, Share capital, Finance, Corporate finance, Financial economics, Stock market

Golden Ocean Group Limited (the Company) advises that a Special General Meeting of the Shareholders of the Company was held on March 26, 2021 at 9:00 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton, Bermuda (the Meeting).

Key Points: 
  • Golden Ocean Group Limited (the Company) advises that a Special General Meeting of the Shareholders of the Company was held on March 26, 2021 at 9:00 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton, Bermuda (the Meeting).
  • The following resolution was in line with the proposal in the notice to the Meeting.
  • The Companys authorized share capital be increased from US$10,000,000.00 divided into 200,000,000 common shares of US$0.05 par value each to US$15,000,000.00 divided into 300,000,000 common shares of US$0.05 par value each by the creation of 100,000,000 common shares of US$0.05 par value each.

GOGL – 2020 Annual General Meeting

Retrieved on: 
Friday, March 26, 2021
Financial capital, Bond valuation, Par value, Valuation, Share capital, Finance, Corporate finance, Financial economics, Stock market

Golden Ocean Group Limited (the Company) advises that a Special General Meeting of the Shareholders of the Company was held on March 26, 2021 at 9:00 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton, Bermuda (the Meeting).

Key Points: 
  • Golden Ocean Group Limited (the Company) advises that a Special General Meeting of the Shareholders of the Company was held on March 26, 2021 at 9:00 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton, Bermuda (the Meeting).
  • The following resolution was in line with the proposal in the notice to the Meeting.
  • The Companys authorized share capital be increased from US$10,000,000.00 divided into 200,000,000 common shares of US$0.05 par value each to US$15,000,000.00 divided into 300,000,000 common shares of US$0.05 par value each by the creation of 100,000,000 common shares of US$0.05 par value each.

Capital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units

Retrieved on: 
Thursday, March 25, 2021
Corporate law, Financial capital, Share capital

A total of 3,854 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Restricted Share Unit of DKK 61.1895.

Key Points: 
  • A total of 3,854 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Restricted Share Unit of DKK 61.1895.
  • Following the share capital increase, the total nominal share capital will be DKK 34,952,241, divided into 34,952,241 shares each with a nominal value of DKK 1.
  • Each share carries one vote at Orphazyme's general meetings and accordingly the total number of voting rights of the company are 34,952,241.
  • Orphazyme is a late-stage biopharmaceutical company pioneering the Heat Shock Protein response for the treatment of neurodegenerative orphan diseases.

Dakshidin Corporation Increases Authorised Share Capital

Retrieved on: 
Tuesday, March 23, 2021
Financial markets, Finance, Corporate law, Corporate finance, Financial economics, Financial capital, Stock market, Equity securities, Share capital, Shares outstanding, Share, Authorised capital

Las Vegas, Nevada--(Newsfile Corp. - March 23, 2021) - Dakshidin Corporation (OTC Pink: DKSC) shareholders representing more than 50% of all outstanding shares voted in favor of increasing the authorised share capital by 50%.

Key Points: 
  • Las Vegas, Nevada--(Newsfile Corp. - March 23, 2021) - Dakshidin Corporation (OTC Pink: DKSC) shareholders representing more than 50% of all outstanding shares voted in favor of increasing the authorised share capital by 50%.
  • Dakshidin Corporation had not issued any shares out of treasury for more than 2 years.
  • The total issued and outstanding during that time was within 0.2% of the total authorised.
  • This increase will allow the company to explore various opportunities, the first of which is expected to be announced shortly.

Worldwide Shares Outstanding Service 2021: Calculate Share Stakes, Regulatory Reporting Levels as Well as Capitalization Figures With the Worldwide Share Outstanding Data - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 16, 2021
Professional services, Finance, Financial markets, Corporate finance, Finance, Financial economics, Stock market, Fundamental analysis, Equity securities, Financial ratios, Earnings per share, Shares outstanding, Market capitalization, Share capital

The number of shares outstanding, shown on a company's balance sheet under the heading "capital stock" is used to calculate key metrics including market capitalization figures, earnings per share (EPS) and share stakes for regulatory reporting levels.

Key Points: 
  • The number of shares outstanding, shown on a company's balance sheet under the heading "capital stock" is used to calculate key metrics including market capitalization figures, earnings per share (EPS) and share stakes for regulatory reporting levels.
  • The Share Outstanding service is comprised of two datasets, Official Shares Outstanding and Daily-Adjusted Shares Outstanding.
  • Official Shares Outstanding Providing official figures sourced directly from local exchanges or company sources, as soon as they are published.
  • The Worldwide Shares Outstanding service provides up-to-date figures from over 100 countries worldwide enabling companies to efficiently calculate figures to comply with exchange regulations or portfolio holding levels.

DGAP-News: windeln.de SE: windeln.de SE successfully completes 10% capital increase - full placement with gross issue proceeds of EUR 1,4 million

Retrieved on: 
Friday, March 12, 2021
Corporate finance, Stock market, Equity securities, Finance, Financial economics, Corporate law, Privat Group, PrivatBank, Dividend, Share capital, Financial capital, Share

The capital increase was accompanied by Quirin Privatbank AG.

Key Points: 
  • The capital increase was accompanied by Quirin Privatbank AG.
  • Through the placement of all 1,098,207 new no-par value bearer shares with a pro-rata amount in the share capital of EUR 1.00 each, and dividend entitlement as from January 1, 2020 ("New Shares"), gross issue proceeds of EUR 1,427,669.10 were generated based on the placement price of EUR 1.30 per New Share.
  • As a result of this capital increase, the Company's share capital was increased to EUR 12,080,280.00.
  • The proceeds from the issue will be used to further strengthen the capital base of the Company.

Travis Perkins: Total Voting Rights

Retrieved on: 
Tuesday, March 2, 2021
Financial markets, Corporate finance, Financial economics, Finance, Stock market, Equity securities, Corporate law, Issued shares, Common stock, Share capital, Share, Treasury stock

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • In conformity with DTR5.6.1R, the Company notifies the market of the following:
    As at the date of this announcement, the Company's issued share capital consists of 252,143,923 ordinary shares with a nominal value of 10 pence each ("Ordinary Shares"), with voting rights.
  • The Company does not hold any Ordinary Shares in Treasury.
  • Therefore, the total number of Ordinary Shares with voting rights is 252,143,923.

GOGL – Private placement: issue of New Shares

Retrieved on: 
Monday, March 1, 2021
Financial markets, Stock market, Finance, Financial economics, Prospectus, Listing, Stock, Share capital, NASDAQ, Exchange, Company

Reference is made to the stock exchange release by Golden Ocean Group Limited (NASDAQ and OSE: GOGL) (Golden Ocean or the "Company) on 17 February 2021 regarding completion of the private placement of new shares in the Company (the "Private Placement").

Key Points: 
  • Reference is made to the stock exchange release by Golden Ocean Group Limited (NASDAQ and OSE: GOGL) (Golden Ocean or the "Company) on 17 February 2021 regarding completion of the private placement of new shares in the Company (the "Private Placement").
  • The new shares have been legally and validly issued and fully paid, and the Company's issued share capital has been increased to USD 9,924.012.20, divided into 198,480,244 issued shares, each with a nominal value of USD 0.05.
  • The new shares are registered under a separate ISIN pending approval of a listing prospectus by the Financial Supervisory Authority of Norway, and will not be listed or tradable on the Oslo Stock Exchange until the listing prospectus is approved.

OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity

Retrieved on: 
Monday, March 1, 2021
Corporate law, Financial capital, Share capital

Applications will be made to the FCA and to the London Stock Exchange for Admission in respect of all the 250,000 Ordinary Shares.

Key Points: 
  • Applications will be made to the FCA and to the London Stock Exchange for Admission in respect of all the 250,000 Ordinary Shares.
  • Following Admission of the new Ordinary Shares, the enlarged Share Capital will be 672,816,302 ordinary shares of no par value.
  • The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO.
  • OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain.